IL237604B - Compositions of enzalutamide - Google Patents
Compositions of enzalutamideInfo
- Publication number
- IL237604B IL237604B IL237604A IL23760415A IL237604B IL 237604 B IL237604 B IL 237604B IL 237604 A IL237604 A IL 237604A IL 23760415 A IL23760415 A IL 23760415A IL 237604 B IL237604 B IL 237604B
- Authority
- IL
- Israel
- Prior art keywords
- enzalutamide
- formulations
- Prior art date
Links
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 title 1
- 229960004671 enzalutamide Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699351P | 2012-09-11 | 2012-09-11 | |
| PCT/US2013/059223 WO2014043208A1 (en) | 2012-09-11 | 2013-09-11 | Formulations of enzalutamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL237604A0 IL237604A0 (en) | 2015-04-30 |
| IL237604B true IL237604B (en) | 2021-07-29 |
Family
ID=49231627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL237604A IL237604B (en) | 2012-09-11 | 2015-03-08 | Compositions of enzalutamide |
Country Status (29)
| Country | Link |
|---|---|
| US (11) | US20140179749A1 (OSRAM) |
| EP (6) | EP4324527A3 (OSRAM) |
| JP (5) | JP6404217B2 (OSRAM) |
| KR (1) | KR102225416B1 (OSRAM) |
| CN (2) | CN109897004A (OSRAM) |
| AU (2) | AU2013315619B2 (OSRAM) |
| BR (1) | BR112015005432B1 (OSRAM) |
| CA (1) | CA2884795C (OSRAM) |
| CY (1) | CY1124729T1 (OSRAM) |
| DK (1) | DK3725778T3 (OSRAM) |
| EA (2) | EA033374B9 (OSRAM) |
| ES (1) | ES2892029T3 (OSRAM) |
| HK (1) | HK1212701A1 (OSRAM) |
| HR (1) | HRP20211423T1 (OSRAM) |
| HU (1) | HUE057701T2 (OSRAM) |
| IL (1) | IL237604B (OSRAM) |
| IN (1) | IN2015DN02875A (OSRAM) |
| LT (1) | LT3725778T (OSRAM) |
| MX (3) | MX363974B (OSRAM) |
| PH (1) | PH12015500525A1 (OSRAM) |
| PL (1) | PL3725778T3 (OSRAM) |
| PT (1) | PT3725778T (OSRAM) |
| RS (1) | RS62676B1 (OSRAM) |
| SI (1) | SI3725778T1 (OSRAM) |
| SM (1) | SMT202100550T1 (OSRAM) |
| TW (1) | TWI673051B (OSRAM) |
| UA (1) | UA117353C2 (OSRAM) |
| WO (1) | WO2014043208A1 (OSRAM) |
| ZA (1) | ZA201501847B (OSRAM) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015005432B1 (pt) | 2012-09-11 | 2023-04-18 | Medivation Prostate Therapeutics Llc | Enzalutamida amorfa, composição farmacêutica contendo a mesma, processo de preparação e uso das mesmas |
| SG10201912719TA (en) | 2012-09-26 | 2020-02-27 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| CA2908957C (en) * | 2013-04-17 | 2021-05-18 | Signal Pharmaceuticals, Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| EA201891397A1 (ru) * | 2014-02-05 | 2019-03-29 | Лек Фармасьютикалз Д.Д. | Твердые фармацевтические композиции антагонистов рецепторов андрогенов |
| CN104356068A (zh) * | 2014-10-30 | 2015-02-18 | 杭州新博思生物医药有限公司 | 恩杂鲁胺新晶型及其制备方法 |
| ES3019912T3 (en) * | 2014-12-05 | 2025-05-21 | Aragon Pharmaceuticals Inc | Anticancer compositions |
| ES2996833T3 (en) * | 2014-12-05 | 2025-02-13 | Aragon Pharmaceuticals Inc | Anticancer compositions |
| WO2016090101A1 (en) * | 2014-12-05 | 2016-06-09 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
| CN104546714A (zh) * | 2015-02-11 | 2015-04-29 | 江苏慧博生物科技有限公司 | 一种恩杂鲁胺胶束制剂及其制备方法 |
| WO2016130819A2 (en) * | 2015-02-11 | 2016-08-18 | Emergent Product Development Seattle Llc | Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins |
| CN104857517B (zh) * | 2015-05-14 | 2018-04-27 | 南京海纳医药科技股份有限公司 | 一种恩杂鲁胺软胶囊及其制备方法 |
| EP3307246A1 (en) | 2015-06-09 | 2018-04-18 | Capsugel Belgium NV | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
| CN105030685B (zh) * | 2015-07-21 | 2018-02-27 | 福格森（武汉）生物科技股份有限公司 | 一种恩杂鲁胺固体分散体口服制剂 |
| WO2017027665A1 (en) | 2015-08-12 | 2017-02-16 | Medivation Prostate Therapeutics, Inc. | Treatment of cancer using a combination of enzalutamide and a cyp3a4 inducer |
| WO2017035263A1 (en) * | 2015-08-24 | 2017-03-02 | Biocryst Pharmaceuticals, Inc. | Compositions comprising a plasma kallikrein inhibitor |
| EP3352760A4 (en) | 2015-09-21 | 2019-03-06 | Aptevo Research and Development LLC | CD3-BINDING POLYPEPTIDES |
| US20180344649A1 (en) | 2015-09-29 | 2018-12-06 | Acorda Therapeutics, Inc. | Sustained release compositions of 4-aminopyridine |
| CN107126419B (zh) * | 2016-02-26 | 2020-06-19 | 石药集团中诺药业（石家庄）有限公司 | 一种奥贝胆酸片剂及其制备方法 |
| EP3487497B1 (en) | 2016-07-21 | 2021-09-08 | Hadasit Medical Research Services and Development Ltd. | Combinations comprising ar antagonists or inhibitors for use in treating glioblastoma |
| CA3036011A1 (en) | 2016-08-20 | 2018-03-01 | Ftf Pharma Private Limited | Pharmaceutical composition comprising an androgen receptor inhibitor |
| JP7109535B2 (ja) * | 2017-04-13 | 2022-07-29 | パウル レモン，ジャン | キサントフモールベースの組成物 |
| RU2019138248A (ru) | 2017-04-28 | 2021-05-28 | Астеллас Фарма Инк. | Фармацевтическая композиция для перорального введения, содержащая энзалутамид |
| JP7282045B2 (ja) | 2017-06-22 | 2023-05-26 | セルジーン コーポレイション | Ｂ型肝炎ウイルス感染を特徴とする肝細胞癌の治療 |
| WO2019016747A1 (en) * | 2017-07-20 | 2019-01-24 | Dr. Reddy's Laboratories Limited | AMORPHOUS SOLID DISPERSIONS OF APALUTAMIDE AND PROCESS FOR THEIR PREPARATION |
| WO2019030691A1 (en) * | 2017-08-08 | 2019-02-14 | Dr. Reddy’S Laboratories Limited | EXTRUDED COMPOSITIONS OF ENZALUTAMIDE |
| CA3079135A1 (en) | 2017-10-16 | 2019-04-25 | Arturo Molina | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| WO2019155416A2 (en) * | 2018-02-09 | 2019-08-15 | Kashiv Pharma Llc | A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens |
| ES2967689T3 (es) * | 2018-04-06 | 2024-05-03 | Capsugel Belgium Nv | Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)] |
| CZ2018234A3 (cs) | 2018-05-21 | 2019-12-04 | Zentiva Ks | Zvýšení rozpustnosti a biodostupnosti enzalutamidu |
| SG11202104208RA (en) * | 2018-10-30 | 2021-05-28 | Peloton Therapeutics Inc | Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof |
| EA202191372A1 (ru) * | 2018-12-14 | 2021-09-16 | Фуджифилм Корпорэйшн | Таблетка и способ получения таблетки |
| CN109432016B (zh) * | 2018-12-26 | 2021-03-02 | 广州中医药大学(广州中医药研究院) | 一种恩杂鲁胺的三元固体制剂及其制备方法 |
| WO2020144647A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Pharmaceutical composition comprising apalutamide dispersed in apple sauce |
| KR20210153038A (ko) | 2019-01-30 | 2021-12-16 | 아라곤 파마슈티컬스, 인코포레이티드 | 전이성 거세-민감성 전립선암의 치료를 위한 항안드로겐 |
| AU2020215177A1 (en) | 2019-01-30 | 2021-08-12 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| EP3968964B1 (en) | 2019-05-16 | 2024-07-10 | leon-nanodrugs GmbH | Method for producing nanoparticles |
| EP3972569A1 (en) | 2019-05-23 | 2022-03-30 | Helm AG | Nanoparticles comprising enzalutamide |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| CA3143111A1 (en) | 2019-06-27 | 2020-12-30 | Synthon B.V. | Process for preparation of enzalutamide |
| CN119424433A (zh) * | 2019-09-18 | 2025-02-14 | 百时美施贵宝公司 | Tyk2抑制剂的剂型 |
| MX2022003347A (es) * | 2019-09-23 | 2022-04-11 | Bionomics Ltd | Formulaciones terapeuticas y usos de las mismas. |
| CA3152909A1 (en) | 2019-10-03 | 2021-04-08 | Synthon Bv | Pharmaceutical composition comprising enzalutamide |
| JP2023500935A (ja) | 2019-11-04 | 2023-01-11 | アラゴン ファーマシューティカルズ，インコーポレイテッド | 重度の肝障害を有する対象における非転移性去勢抵抗性前立腺癌の治療のためのアンドロゲン受容体阻害剤 |
| JP2023524661A (ja) * | 2020-05-06 | 2023-06-13 | ディスラプティヴ ファーマ エービー | 新規非晶質活性医薬成分 |
| AR118925A1 (es) * | 2020-05-13 | 2021-11-10 | Novocap S A | Solución líquida concentrada de antiandrógenos no esteroideos y procedimiento para preparar la solución |
| WO2021240206A1 (en) | 2020-05-24 | 2021-12-02 | Lotus International Pte. Ltd. | Enzalutamide formulation |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| CN114053243B (zh) * | 2020-08-05 | 2024-11-12 | 齐鲁制药有限公司 | 一种恩扎卢胺软胶囊及其制备方法 |
| WO2022049523A1 (en) | 2020-09-04 | 2022-03-10 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| FI4210700T3 (fi) * | 2020-09-09 | 2025-09-16 | Crinetics Pharmaceuticals Inc | Somatostatiinimodulaatorin formulaatioita |
| AU2021342517A1 (en) * | 2020-09-18 | 2023-05-11 | Bristol-Myers Squibb Company | Dosage forms for tyk2 inhibitors comprising swellable cores |
| CN112022812B (zh) * | 2020-11-03 | 2021-01-29 | 上海亚盛医药科技有限公司 | 一种包含杂环类化合物的组合物、其制备方法和应用 |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| BR112023022789A2 (pt) | 2021-07-07 | 2024-02-27 | Bdr Pharmaceuticals International Private Ltd | Composição farmacêutica na forma de uma solução oral de enzalutamida, composição farmacêutica na forma de uma solução oral de enzalutamida e método para preparar uma solução oral de enzalutamida |
| CN115721612B (zh) * | 2021-08-26 | 2024-07-26 | 上海宣泰医药科技股份有限公司 | 一种恩扎卢胺固体制剂颗粒及其制备方法 |
| CN118251213A (zh) * | 2022-01-19 | 2024-06-25 | 四川科伦药物研究院有限公司 | 固体分散体及其制备方法和包含其的药物组合物 |
| CN114224832A (zh) * | 2022-02-11 | 2022-03-25 | 明度智云(浙江)科技有限公司 | 一种恩杂鲁胺注射剂及其制备方法和应用 |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
| WO2023244617A1 (en) * | 2022-06-13 | 2023-12-21 | Virginia Polytechnic Institute And State University | Amphiphilic cellulose derivatives, methods of making, and uses thereof |
| TW202416960A (zh) * | 2022-06-17 | 2024-05-01 | 美商特朗奎斯治療股份有限公司 | 2-芳基苯并咪唑化合物之調配物 |
| CN115887395A (zh) * | 2022-11-18 | 2023-04-04 | 上海药坦药物研究开发有限公司 | 恩杂鲁胺固体分散体制剂及其制备方法和应用 |
| EP4374853A1 (en) | 2022-11-22 | 2024-05-29 | Lotus Pharmaceutical Co., Ltd. | Solid formulation of enzalutamide |
| EP4651860A1 (en) | 2023-01-18 | 2025-11-26 | HELM Pharmaceuticals GmbH | Crystalline nanoparticles comprising enzalutamide |
| WO2024191660A2 (en) * | 2023-03-10 | 2024-09-19 | Yale University | Compositions and methods for treating steroid hormone-related diseases or disorders |
| WO2024189186A1 (en) | 2023-03-16 | 2024-09-19 | Bayer Consumer Care Ag | Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer |
| WO2025052925A1 (ja) * | 2023-09-08 | 2025-03-13 | 沢井製薬株式会社 | エンザルタミド固体分散体及びその製造方法、並びにエンザルタミド含有製剤及びその製造方法 |
| KR20250058470A (ko) | 2023-10-23 | 2025-04-30 | 케이원팜 주식회사 | 안정성과 용출특성이 향상된 신규 엔잘루타마이드 함유 조성물 및 이의 제조방법 |
| EP4520322A1 (en) * | 2023-12-06 | 2025-03-12 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical compositions containing enzalutamide |
| WO2025125565A1 (en) | 2023-12-13 | 2025-06-19 | Krka, D.D., Novo Mesto | Tablet comprising enzalutamide |
| KR20250100928A (ko) | 2023-12-27 | 2025-07-04 | 케이원팜 주식회사 | 생체이용률이 개선된 엔잘루타마이드 약학 조성물 및 이의 제조방법 |
| CN118001243B (zh) * | 2024-01-31 | 2024-10-22 | 四川鲁徽制药有限责任公司 | 一种恩杂鲁胺口腔崩解片及其制备方法 |
| WO2025212071A1 (en) * | 2024-04-05 | 2025-10-09 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | A solid dispersion of enzalutamide |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656651A (en) * | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
| TW486370B (en) | 1996-12-25 | 2002-05-11 | Yamanouchi Pharma Co Ltd | Rapidly disintegrable pharmaceutical composition |
| DE69837903T2 (de) | 1997-08-11 | 2008-02-14 | Pfizer Products Inc., Groton | Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit |
| EP1745774A3 (en) | 1997-08-11 | 2007-04-11 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
| IN191496B (OSRAM) | 1999-07-30 | 2003-12-06 | Ranbaxy Lab Ltd | |
| AR027656A1 (es) | 2000-03-16 | 2003-04-09 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa |
| CZ20032225A3 (cs) | 2001-02-27 | 2003-11-12 | Astrazeneca Ab | Farmaceutická formulace |
| SE0103424D0 (sv) | 2001-10-15 | 2001-10-15 | Astrazeneca Ab | Pharmaceutical formulation |
| GB2383042A (en) | 2001-10-18 | 2003-06-18 | Cipla Ltd | Amorphous alendronate sodium |
| SE0103839D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Pharmaceutical formulation & product |
| PL371593A1 (en) * | 2002-02-01 | 2005-06-27 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
| EP1499662A1 (en) * | 2002-04-18 | 2005-01-26 | Avecia Limited | Prepation of a conjugated molecule and materials for use therein |
| JP4249950B2 (ja) | 2002-06-28 | 2009-04-08 | 富士フイルム株式会社 | 紙管切断装置及び紙管切断方法 |
| US20050020675A1 (en) * | 2003-02-21 | 2005-01-27 | Parthasaradhi Reddy Bandi | Bicalutamide polymorphs |
| WO2005095950A1 (en) | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Method and device for evaluation of pharmaceutical compositions |
| US7709517B2 (en) * | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| RU2448096C3 (ru) | 2005-05-13 | 2017-12-11 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Диарилгидантоины |
| EP1885338A1 (en) | 2005-05-19 | 2008-02-13 | Pfizer, Inc. | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
| EP1909762A2 (en) | 2005-07-28 | 2008-04-16 | Isp Investments Inc. | Amorphous efavirenz and the production thereof |
| WO2007126765A2 (en) | 2006-03-27 | 2007-11-08 | The Regents Of The University Of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
| US8613946B2 (en) | 2006-12-21 | 2013-12-24 | Isp Investment Inc. | Carotenoids of enhanced bioavailability |
| US20100151035A1 (en) | 2007-03-13 | 2010-06-17 | Sandoz Ag | Pharmaceutical compositions of poorly soluble drugs |
| CN102083467B (zh) * | 2008-03-11 | 2013-12-25 | Aska制药株式会社 | 固体分散体及其药物组合物、以及它们的制备方法 |
| JP5511942B2 (ja) | 2009-04-03 | 2014-06-04 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | 組成物及びその使用 |
| US20100297194A1 (en) * | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| MX2012009782A (es) * | 2010-02-24 | 2012-11-29 | Medivation Prostate Therapeutics Inc | Procesos para la sintesis de diariltiohidantoina y compuestos de diarilhidantoina. |
| MY156888A (en) * | 2010-03-10 | 2016-04-15 | Abbvie Bahamas Ltd | Solid Compositions |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| HRP20180902T1 (hr) | 2012-06-07 | 2018-08-24 | Sloan-Kettering Institute For Cancer Research | Kristalni oblici modulatora receptora androgena |
| US9515365B2 (en) * | 2012-08-10 | 2016-12-06 | Keyssa, Inc. | Dielectric coupling systems for EHF communications |
| KR20150053963A (ko) | 2012-09-11 | 2015-05-19 | 닥터 레디스 레보러터리즈 리미티드 | 엔잘루타마이드 다형태 및 그의 제조 |
| BR112015005432B1 (pt) | 2012-09-11 | 2023-04-18 | Medivation Prostate Therapeutics Llc | Enzalutamida amorfa, composição farmacêutica contendo a mesma, processo de preparação e uso das mesmas |
| US9713594B2 (en) | 2012-09-11 | 2017-07-25 | Bend Research, Inc. | Methods for making pharmaceutical solid dosage forms of spray-dried dispersions |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| RU2019138248A (ru) | 2017-04-28 | 2021-05-28 | Астеллас Фарма Инк. | Фармацевтическая композиция для перорального введения, содержащая энзалутамид |
| US20190208236A1 (en) | 2018-01-02 | 2019-07-04 | Source Digital, Inc. | Coordinates as ancillary data |
| CA3152909A1 (en) | 2019-10-03 | 2021-04-08 | Synthon Bv | Pharmaceutical composition comprising enzalutamide |
-
2013
- 2013-09-11 BR BR112015005432-3A patent/BR112015005432B1/pt active IP Right Grant
- 2013-09-11 CA CA2884795A patent/CA2884795C/en active Active
- 2013-09-11 DK DK20177837.0T patent/DK3725778T3/da active
- 2013-09-11 HK HK16100714.7A patent/HK1212701A1/zh unknown
- 2013-09-11 EP EP23205739.8A patent/EP4324527A3/en not_active Withdrawn
- 2013-09-11 UA UAA201503119A patent/UA117353C2/uk unknown
- 2013-09-11 TW TW102132800A patent/TWI673051B/zh active
- 2013-09-11 EA EA201500314A patent/EA033374B9/ru not_active IP Right Cessation
- 2013-09-11 MX MX2015003140A patent/MX363974B/es active IP Right Grant
- 2013-09-11 US US14/023,878 patent/US20140179749A1/en not_active Abandoned
- 2013-09-11 EP EP13766437.1A patent/EP2895463A1/en not_active Withdrawn
- 2013-09-11 EP EP22197255.7A patent/EP4169908A1/en not_active Withdrawn
- 2013-09-11 SM SM20210550T patent/SMT202100550T1/it unknown
- 2013-09-11 EA EA201991484A patent/EA201991484A1/ru unknown
- 2013-09-11 RS RS20211117A patent/RS62676B1/sr unknown
- 2013-09-11 LT LTEP20177837.0T patent/LT3725778T/lt unknown
- 2013-09-11 EP EP21190086.5A patent/EP3971167A1/en not_active Withdrawn
- 2013-09-11 HR HRP20211423TT patent/HRP20211423T1/hr unknown
- 2013-09-11 EP EP20177837.0A patent/EP3725778B1/en active Active
- 2013-09-11 HU HUE20177837A patent/HUE057701T2/hu unknown
- 2013-09-11 EP EP24198653.8A patent/EP4450130A3/en active Pending
- 2013-09-11 PL PL20177837T patent/PL3725778T3/pl unknown
- 2013-09-11 KR KR1020157009040A patent/KR102225416B1/ko active Active
- 2013-09-11 ES ES20177837T patent/ES2892029T3/es active Active
- 2013-09-11 AU AU2013315619A patent/AU2013315619B2/en active Active
- 2013-09-11 CN CN201811517651.2A patent/CN109897004A/zh active Pending
- 2013-09-11 WO PCT/US2013/059223 patent/WO2014043208A1/en not_active Ceased
- 2013-09-11 SI SI201331927T patent/SI3725778T1/sl unknown
- 2013-09-11 US US14/023,637 patent/US20140100256A1/en not_active Abandoned
- 2013-09-11 PT PT201778370T patent/PT3725778T/pt unknown
- 2013-09-11 CN CN201380055471.6A patent/CN105358535B/zh active Active
- 2013-09-11 IN IN2875DEN2015 patent/IN2015DN02875A/en unknown
- 2013-09-11 JP JP2015531335A patent/JP6404217B2/ja active Active
-
2014
- 2014-09-10 US US14/481,986 patent/US20140378517A1/en not_active Abandoned
-
2015
- 2015-03-08 IL IL237604A patent/IL237604B/en unknown
- 2015-03-11 PH PH12015500525A patent/PH12015500525A1/en unknown
- 2015-03-11 MX MX2021000007A patent/MX2021000007A/es unknown
- 2015-03-11 MX MX2019003984A patent/MX2019003984A/es unknown
- 2015-03-18 ZA ZA2015/01847A patent/ZA201501847B/en unknown
-
2016
- 2016-02-08 US US15/018,078 patent/US20170027910A1/en not_active Abandoned
- 2016-09-09 JP JP2016176557A patent/JP2016204392A/ja active Pending
- 2016-09-16 US US15/267,352 patent/US20170224624A1/en not_active Abandoned
-
2018
- 2018-01-15 AU AU2018200316A patent/AU2018200316A1/en not_active Abandoned
- 2018-01-26 JP JP2018011759A patent/JP2018087206A/ja active Pending
- 2018-07-24 US US16/044,255 patent/US20190209476A1/en not_active Abandoned
-
2019
- 2019-04-01 US US16/371,618 patent/US20200060976A1/en not_active Abandoned
- 2019-08-08 JP JP2019146714A patent/JP6932746B2/ja active Active
-
2021
- 2021-08-17 JP JP2021132868A patent/JP2021178871A/ja active Pending
- 2021-09-14 CY CY20211100809T patent/CY1124729T1/el unknown
-
2022
- 2022-11-11 US US17/985,220 patent/US12447128B2/en active Active
- 2022-11-11 US US17/985,235 patent/US11839689B2/en active Active
-
2024
- 2024-10-30 US US18/931,464 patent/US20250049721A1/en active Pending
- 2024-12-04 US US18/967,829 patent/US20250090465A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201501847B (en) | Formulations of enzalutamide | |
| PL2877155T3 (pl) | Formulacje opioidowe | |
| ZA201407373B (en) | Novel pharmaceutical formulations | |
| SG11201500412TA (en) | Vaccine compositions | |
| HUE064884T2 (hu) | Bendamusztin kiszerelések | |
| IL289157A (en) | Opioid compounds | |
| ZA201406082B (en) | Use of ccr3-inhibitors | |
| EP4342536C0 (en) | BROMOCRIPTINE FORMULATIONS | |
| ZA201306000B (en) | Stable formulation | |
| SG11201504134SA (en) | External preparation | |
| GB201501016D0 (en) | Preparation of 18F-fluciclovine | |
| GB201312378D0 (en) | Structure of shoe | |
| IL217807A0 (en) | Therapeutic compositions | |
| GB201210530D0 (en) | Extended release formulations | |
| ZA201502350B (en) | Solid form of hihydro-pyrido-oxazine derivative | |
| PL2908859T3 (pl) | Formulacje arypiprazolu | |
| HK40116766A (en) | Formulations of enzalutamide | |
| HK40108713A (en) | Formulations of enzalutamide | |
| GB201206178D0 (en) | Formulations | |
| IL233879A0 (en) | Dry powdered dnase i preparations | |
| TWM433525U (en) | Structure of calorifier | |
| HUE036665T2 (hu) | Dihidro-pirido-oxazin származék szilárd formái | |
| GB201211247D0 (en) | Improved formulation | |
| GB201216165D0 (en) | Virtues iBrush | |
| GB201211406D0 (en) | Pharmaceutical formulations |